Pressor Effects of Endogenous Opioid System During Acute Episodes of Blood Pressure Increases in Hypertensive Patients

Hypertension

Volumn 29, Issue 1, 1997, Pages 105-110

  Fontana, Fiorella ^a   Bernardi, Pasquale ^a   Spampinato, Sante ^a   Boschi, Stefano ^a   De Iasio, Rosaria ^a   Grossi, Gabriele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA ENDORPHIN; CATECHOLAMINE; DYNORPHIN B; ENDOTHELIN 1; METENKEPHALIN; NALOXONE; OPIATE ANTAGONIST;

ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CATECHOLAMINE RELEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; HORMONE DETERMINATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRESSOR RESPONSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STRESS; SYSTOLIC BLOOD PRESSURE;

ATRIAL NATRIURETIC FACTOR; BETA-ENDORPHIN; BLOOD PRESSURE; DYNORPHINS; ENDORPHINS; ENDOTHELIN-1; ENKEPHALIN, METHIONINE; FEMALE; HEART RATE; HUMANS; HYPERTENSION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; NOREPINEPHRINE; OPIOID PEPTIDES; STRESS; STRESS, PSYCHOLOGICAL;

EID: 0031051745     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.29.1.105     Document Type: Article

References (45)

1. Caffrey JL, Wooldridge CB, Gaugl JF. Naloxone enhances myocardial responses to isoproterenol in dog isolated heart-lung. Am J Physiol. 1986;250:H749-H754.
2. Curtis MT, Lefer AM. Protective actions of naloxone in hemorrhagic shock. Am J Physiol. 1980;239:H416-H421.
3. Hughes J, Kosterlitz HW, Smith TW. The distribution of methionine-enkephalin and leucine-enkephalin in the brain and peripheral tissues. Br J Pharmacol. 1977;61:639-647.
4. Spampinato S, Goldstein A. Immunoreactive dynorphin in rat tissues and plasma. Neuropeptides. 1983;3:193-212.
5. Viveros OH, Diliberto EJ, Hazum E, Chang KJ. Opiate-like materials in the adrenal medulla: evidence for storage and secretion with catecholamines. Mol Pharmacol. 1979;16:1101-1108.
6. Stock G, Schmelz M, Knuepfer MM, Forssmann WG. Functional and anatomic aspects of central nervous cardiovascular regulation. In: Ganten D, Pfaff D, eds. Central Cardiovascular Control. New York, NY: Springer-Verlag; 1983:1-24.
7. Yang HYT, Hong JS, Costa E. Regional distribution of leu- and metenkephalin in rat brain. Neuropharmacology. 1977;16:303-307.
8. Gaddis RR, Dixon WR. Modulation of peripheral adrenergic neurotransmission by methionine-enkephalin. J Pharmacol Exp Ther. 1982;221:282-287.
9. Xie CW, Yin LY, Xie XZ, Gao XM, Xia ZA, Chang JK, Tang J. A dynorphin peptide induces hypotension by stimulating the release of atrial natriuretic peptide from rat atrium. Life Sci. 1988;42:1117-1122.
10. Catlin DH, Gorelick DA, Gerner RH. Clinical pharmacology of beta-endorphin in depression and schizophrenia. In: Verebey K, ed. Opioids in Mental Illness: Theories, Clinical Observations, and Treatment Possibilities. New York, NY: Annals of the New York Academy of Sciences; 1982:434-447.
11. Chalmers J, Pilowsky P. Brainstem and bulbospinal neurotransmitter systems in the control of blood pressure. J Hypertens. 1991;9:675-694.
12. Zamir N, Simantov R, Segal M. Pain sensitivity and opioid activity in genetically and experimentally hypertensive rats. Brain Res. 1980;184:299-310.
13. Feuerstein G, Siren AL. The opioid peptides: a role in hypertension? Hypertension. 1987;9:561-565.
14. Guardigli G, Fontana F, Ventura C, Spagnolo N, Bastagli L, Puddu P, Bernardi P. Endogenous opioids and hypertensive crisis in patients with acute cerebrovascular accident. J Endocrinol Invest. 1989;12(suppl 4):9-12.
15. Weiner H. Personality factors and the importance of emotional stresses in hypertension. In: Genest J, Koiw E, Kuchel O, eds. Hypertension: Physiopathology and Treatment. New York, NY: McGraw-Hill Book Co; 1977:661-673.
16. Leino T, Leppaluoto J, Huttunen P, Ruokonen A, Kuronen P. Neuroendocrine responses to real and simulated BA Hawk MK 51 flight. Aviat Space Environ Med. 1995;66:108-113.
17. Hirata Y, Itoh KI, Ando K, Endo M, Marumo F. Plasma endothelin levels during surgery. N Engl J Med. 1989;321:1686.
18. Fontana F, Bernardi P, Merlo Pich E, Capelli M, Bortoluzzi L, Spampinato S, Canossa M. Relationship between plasma atrial natriuretic factor and opioid peptide levels in healthy subjects and in patients with acute congestive heart failure. Eur Heart J. 1993;14:219-225.
19. Fontana F, Bernardi P, Merlo Pich E, Boschi S, De Iasio R, Capelli M, Carboni L, Spampinato S. Endogenous opioid system and atrial natriuretic factor in normotensive offspring of hypertensive parents at rest and during exercise test. J Hypertens. 1994;12:1285-1290.
20. Bernardi P, Fontana F, Merlo Pich E, Spampinato S, Canossa M. Plasma endogenous opioid levels in acute myocardial infarction patients, with and without pain. Eur Heart J. 1992;13:1074-1079.
21. Grossi G, Bargossi AM, Lucarelli C, Paradisi R, Sprovieri C, Sprovieri G. Improvements in automated analysis of catecholamine and related metabolites in biological samples by column switching high-performance liquid chromatography. J Chromatogr. 1991;541:273-284.
22. Fontana F, Bernardi P, Spagnolo N, Capelli M. Plasma atrial natriuretic factor in low output heart failure syndromes. Klin Wochenschr. 1990;68:313-319.
23. Goldstein DS. Plasma catecholamines and essential hypertension: an analytical review. Hypertension. 1983;5:86-89.
24. Esler M. Sympathetic activity in experimental and human hypertension. In: Zanchetti A, Mancia G, eds. Handbook of Hypertension, Vol 17: Pathophysiology of Hypertension. Amsterdam, Netherlands: Elsevier Science; 1997:628-673.
25. Holaday JW. Cardiovascular effects of endogenous opiate systems. Annu Rev Pharmacol Toxicol. 1983;23:541-594.
26. McCubbin JA, Surwit RS, Williams RB Jr. Endogenous opiate peptides, stress reactivity, and risk for hypertension. Hypertension. 1985;7:808-811.
27. McCubbin JA, Surwit RS, Williams RB, Nemeroff CB, McNeilly M. Altered pituitary hormone response to naloxone in hypertension development. Hypertension. 1989;14:636-644.
28. Kjaer A, Knigge U, Bach FW, Warberg J. Stress-induced secretion of pro-opiomelanocortin-derived peptides in rats: relative importance of the anterior and intermediate pituitary lobes. Neuroendocrinology. 1995;61:167-172.
29. Gaillet S, Alonso G, Le Borgne R, Barbanel G, Malaval F, Assenmacher I, Szafarczyk A. Effects of discrete lesions in the ventral noradrenergic ascending bundle on the corticotropic stress response depend on the site of the lesion and on the plasma levels of adrenal steroids. Neuroendocrinology. 1993;58:408-419.
30. Jarry H, Dietrich A, Barthel A, Giesler A, Wuttke W. In vivo demonstration of a paracrine, inhibitory action of met-enkephalin on adrenomedullary catecholamine release in the rat. Endocrinology. 1989;125:624-629.
31. Quock RM, Kouchich FJ, Vaughn LK, Fries DS. Narcotic antagonist-induced hypotension in the spontaneously hypertensive rat. Life Sci. 1985;37:819-826.
32. Schaz K, Stock G, Simon W, Schlor KH, Unger T, Rockhold R, Ganten D. Enkephalin effects on blood pressure, heart rate, and baroreceptor reflex. Hypertension. 1980;2:395-407.
33. Naranjo JR, Urdin MC, Borrel J, Fuentes JA. Evidence for a central but not adrenal opioid mediation in hypertension induced by brief isolation in the rat. Life Sci. 1986;38:1923-1930.
34. Schulteis G, Martinez JL Jr. Peripheral modulation of learning and memory: enkephalins as a model system. Psychopharmacology. 1992;109:347-364.
35. Martinez JL Jr, Schulteis G, Weinberger SB. How to increase and decrease the strength of memory traces: the effects of drugs and hormones. In: Martinez JL Jr, Kesner RP, eds. Learning and Memory, A Biological View. New York, NY: Academic Press; 1991:149-198.
36. Ngai SH, Berkowitz BA, Yang JC, Hempstead J, Spector S. Pharmacokinetics of naloxone in rats and in man. Anesthesiology. 1976;44:398-401.
37. Farsang C, Kapocsi J, Juhasz I, Kunos G. Possible involvement of an endogenous opioid in the antihypertensive effect of clonidine in patients with essential hypertension. Circulation. 1982;66:1268-1272.
38. Gayle AO, Olson RD, Kastin AJ. Endogenous opiates: 1993. Peptides. 1994;15:1513-1556.
39. Louisy F, Guezennec CY, Lartigue M, Aldigier JC, Galen FX. Influence of endogenous opioids on atrial natriuretic factor release during exercise in man. Eur J Appl Physiol. 1989;59:34-38.
40. Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW. Endogenous opioid peptides: multiple agonists and receptors. Nature. 1977;267:495-501.
41. Naruse M, Kawana M, Hifumi S, Naruse K, Yoshihara I, Oka T, Kato Y, Monzen C, Kurimoto F, Ohsumi K, Hosoda S, Demura H. Plasma immunoreactive endothelin, but not thrombomodulin, is increased in patients with essential hypertension and ischemic heart disease. J Cardiovasc Pharmacol. 1991;17(suppl 7):S471-S474.
42. Nava E, Luscher F. Endothelium-derived vasoactive factors in hypertension: nitric oxide and endothelin. J Hypertens. 1995;13(suppl 2):S39-S48.
43. Pacher R, Bergler-Klein J, Globits S, Teufelsbauer H, Shuller M, Krauter A, Ogris E, Rodler S, Wutte M, Hartter E. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol. 1993;71:1293-1299.
44. Shihiri M, Hirata Y, Ando K, Emori T, Ohta K, Kimoto S, Ogura M, Inoue A, Marumo F. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension. 1990;15:493-496.
45. Tomita K, Ujiie K, Nakanishi T, Tomura S, Matsuda O, Ando K, Shichiri M, Hirata Y, Marumo F. Plasma endothelin levels in patients with acute renal failure. N Engl J Med. 1990;321:1127. Letter.